Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus

Developing Vaccines against Respiratory Syncytial Virus Infection

s S9 Developing Vaccines against Respiratory Syncytial Virus Infection Jun Chang Division of Life & Pharmaceutical Sciences, Ewha Womans University, 11-1 Dae-Hyun Dong, Seo-Dae-Mun Gu, Seoul 120-750, Korea. Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract disease in infancy and early childhood. Despite its importance as a pathogen, there is no licensed vaccin...

Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

Respiratory syncytial virus (RSV) and the human parainfluenza viruses (PIVs) are enveloped nonsegmented negative-strand RNA viruses of the paramyxovirus family. RSV is the leading cause of severe viral respiratory disease in infants and children, and in the United States RSV is responsible for 73,000 to 126,000 annual hospitalizations of infants younger than 1 year of age (1). Two antigenic sub...

Respiratory syncytial virus vaccines.

Respiratory syncytial virus (RSV) is the most important cause of viral lower respiratory tract illness (LRI) in infants and children worldwide and causes significant LRI in the elderly and in immunocompromised patients. The goal of RSV vaccination is to prevent serious RSV-associated LRI. There are several obstacles to the development of successful RSV vaccines, including the need to immunize v...

Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine

The non-specific effects (NSEs) of vaccines have been discussed for their potential long-term beneficial effects beyond direct protection against a specific pathogen. Cold-adapted, live attenuated influenza vaccine (CAIV) induces local innate immune responses that provide a broad range of antiviral immunity. Herein, we examined whether X-31ca, a donor virus for CAIVs, provides non-specific cros...

Development of an Attenuated Live Virus Vaccine against Sheep Pox